Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Apr 1;86(4):450-454.
doi: 10.1097/QAI.0000000000002586.

Brief Report: Impact of ART on Maternal Health After Cessation of Breastfeeding

Sean S Brummel  1 , Taha E Taha  2 , Konstantia Nadia Angelidou  1 , Friday Saidi  3 , Patience Atuhaire  4 , Dingase Dula  5 , Dhayendre Moodley  6 , Allen Matubu  7 , Gift Chareka  7 , Neetal Nevrekar  8 , Tichaona Vhembo  9 , Lee Fairlie  10 , Gerhard Theron  11 , Pendo Mlay  12 , Kathleen George  13 , Michael Basar  14 , Nahida Chakhtoura  15 , Renee Browning  16 , Mary Glenn Fowler  17 , Judith S Currier  18 ; IMPAACT 1077BF/FF PROMISE Study Team
Affiliations
Randomized Controlled Trial

Brief Report: Impact of ART on Maternal Health After Cessation of Breastfeeding

Sean S Brummel et al. J Acquir Immune Defic Syndr. .

Abstract

IMPAACT PROMISE 1077BF/FF was a sequentially randomized study of pregnant and postpartum women living with HIV to investigate the efficacy and safety of antiretroviral therapy (ART). This Maternal Health Component investigated efficacy for the risk of developing AIDS or death; and safety among women randomized to continue ART (CTART: N = 289) or discontinue ART (N = 268) after cessation of breastfeeding or after confirmation of infant infection. No AIDS-defining illnesses were reported during follow-up in either arm. Adverse events of grade 3 or higher were more frequent in the CTART arm [hazard ratio = 1.78, 95% confidence interval: (1.05 to 3.02), P-value = 0.03]. The difference in adverse events in the 2 groups was mostly driven by moderate weight loss for women on the CTART arm.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

FIGURE 1.
FIGURE 1.
CD4 cell counts cells/mm3 and log HIV-RNA over time with median, 25th and 75th percentiles; percentage of participants with (A) CD4 cell percentage <350 cells/mm3 and (B) HIV-RNA ≤400 copies. Both subfigures used the midpoint between visits to define the number of participants contributing to the data.
See this image and copyright information in PMC

References

    1. Organization WH. Guideline on When to Start Antiretroviral Therapy and on Pre-exposure Prophylaxis for HIV. World Health Organization; 2015. Available at: https://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/. - PubMed
    1. Anglemyer A, Horvath T, Rutherford G. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. JAMA. 2013;310:1619–1620. - PubMed
    1. Group ISS, Lundgren JD, Babiker AG, et al. . Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807. - PMC - PubMed
    1. Currier JS, Britto P, Hoffman RM, et al. . Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 >/= 400 cells/mm3. PLoS One. 2017;12:e0176009. - PMC - PubMed
    1. Hoffman RM, Angelidou KN, Brummel SS, et al. . Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial. HIV Clin Trials. 2018;19:209–224. - PMC - PubMed

Publication types

Substances